2015
Strategic Considerations for the U.S. Pharmaceutical Industry
Cambridge
Healthtech Advisors |
A Collection of Interviews by Thomson CenterWatch
Courtesy of: CenterWatch, a division of Thomson Healthcare
|
|
Breathing
New Life into Structure-Based Design
Author: Vicki Glaser
|
An Update on
Radio-Immunotherapy
Roger Macklis, M.D., Vipul Thakkar, M.D., and Damodar Gupta, Ph.D.
The Cleveland Clinic Foundation, Department of Radiation Oncology, Cleveland, Ohio |
Biological
Functions of MicroRNAs
Enal Razvi, Ph.D. Biotechnology Industry Analyst, San Francisco, California, USA
|
Biomarkers for
Development of Cancer Vaccines
Mike Whelan et al St George's Hospital Medical School
|
Bio-IT World Briefing On: Boosting Productivity In Healthcare
Report fee and download underwritten by Hewlett Packard
|
|
Break
Old Rules Get Results
Realization
Technologies, Inc.
|
|
Confronting
the Social Context of Science
by Carl M
.Cohen and Suzanne L. Cohen, Cold Spring Harbor Laboratory Press,
2005.
|
Common Factors Impacting the Utility and Commercialization of Any Cell Therapy
Nancy L. Parenteau, Ph.D. Parenteau BioConsultants, LLC
|
Current Challenges of Real-Time PCR
Quantitation.
Jorge A. Garces, Genzyme
Genetics
|
Creating an Alliance Management
Capability
by Stuart Kliman &
Christopher Hiserman
|
|
Development of histone deacetylase inhibotors for cancer treatment
|
Diagnosis, Prognosis, and Therapy Selection
Article from Genetic Engineering News Magazine
|
Drug
Development: Last Frontier of Automation
Dr. Lafayette “Fate” Thompson President and CEO, iAdvantage
Software, Inc
|
Drug-Induced
Torsade de Pointes and Implications for Drug Development
by Robert R. Fenichel, M.D., Ph.D.(1), Marek
Malik, Ph.D., M.D.(2),
Charles Antzelevitch, Ph.D.(3), Michael Sanguinetti, Ph.D.(4), Dan M.
Roden, M.D.(5),
Silvia G. Priori, M.D., Ph.D.(6), Jeremy N. Ruskin, M.D.(7), Raymond J.
Lipicky, M.D.(8),
and Lou Cantilena, M.D., Ph.D.(9)
|
NEW!
Doubling IT Innovation Spending: Laying the Foundation for IT-Enabled Business Process, Supply Chain, and Service Innovation in the Pharmaceutical
Industry
By Dr. Chris Asakiewicz
|
The Emergence of Translational Research
BioPerspectives
|
Enterprise Strategy Execution
ActiveStrategy |
Essentials
In Recombinant Protein Process Development
Dr. Stephen Hughes, Researche, USDA |
Expression of Interest
Stephen Chambers, Ph.D., Head of Gene Expression, Vertex Pharmaceuticals Inc. |
Exploiting the
Untapped Promise of Drug Repositioning
Authored by Gene Logic |
Epigenetic Gene Regulation: Early
Environmental Exposures (Future Medicine)
Dana C. Dolinoy, Duke University Medical Center, Department of Radiation Oncology, University Program in Genetics and Genomics, and Integrated Toxicology Program
|
NEW!
Fix Software Security Vulnerabilities Instantly
Healthcare Security Whitepaper from Blue Lane Technologies
|
NEW! Falling Short of True Partnering Excellence: Five Trouble Spots and What to Do About Them
Stuart Kliman and Renee Jansen
|
Genome-Based
Biomarkers for Adverse Drug Effects, Patient Enrichment and Prediction of
Drug Response, and Their Incorporation Into Clinical Trial Design
Thomas J White, Celera Genomics
|
NEW!
Growth and Outsourcing: Advantages of the Virtual Integrated Model
Harry Atkins, Senior Director, Alliance Management, Endo Pharmaceuticals, Inc. |
|
Hepatic
Drug Transport Studies
By Ian J. Mehr, PhD, MBA
|
High
Throughput Screening of Metabolic Stability in Drug Discovery
Wyeth Research, Princeton |
How to Choose the Right Molecular
Diagnostics Technology using a Decision Analysis Matrix
Dr.
Jorge A. Leon, and Dr. Dawn Caruso, Leomics Associates, Inc.
|
How To Make
Dendritic Cells Work in Cancer
Michael R. Shurin, Gurkamal S. Chatta. University of Pittsburgh Medical Center and University of
Pittsburgh Cancer Institute, Pittsburgh, PA |
Implementing an
Alliance-Dependent Strategy
by Stuart Kliman, Larraine Segil and Laura Judy Visioni
|
Integrating
Pharmacology and in vivo Cancer Models in Preclinical and
Clinical Drug Development.
Peter J. Houghton, Chair, Molecular
Pharmacology,
St. Jude Children’s Research Hospital
|
|
LC-ICP-MS: A Maturing Bioanalytical Alternative
For Metabolite Profiling and Mass-Balance Studies wpc
Jaap Wieling, Ph.D., Managing Director, Xendo Labs
|
|
Modulation Angiogenesis Pathway Using siRNA Inhibitors
Patrick Lu, Ph.D., Executive Vice President, Intradigm Corporation
|
Multi-color fluorescent proteins for in vivo imaging
Robert M. Hoffman, AntiCancer, Inc.
|
NEW!
Notes of a Protein Crystallographer: Quo
Vadis Structural Biology?
Cele Abad-Zapatero
|
Nucleic
Acid Quantification and Disease Outcome Prediction in Colorectal
Cancer
Authored by: Stephen A Bustin, University of London, Institute of
Cell and Molecular Science, Barts and the London, Queen Mary’s
School of Medicine and Dentistry, London, UK
|
Magnetic
Micro- and Nano-Particle-Based Targeting for Drug and Gene Delivery
Authored by: Jon Dobson Keele University
|
Negotiating as a Cross-functional Project Manager: Lessons from Alliance Management
by Jeremy Ahouse, Ph.D., ImmunoGen, Inc. and David Fontana, Ph.D., PMP, ZymoGenetics
|
‘Omics’-Based
Imaging in Cancer Detection and Therapy
Peter Oehr University of Bonn,Bio-Med-PharmaConsulting, Personalized
Medicine
|
NEW!
Outsourcing Virtually Everything: Making the Semi-Virtual Model Work
Harry Atkins, Senior Director, Alliance Management, Endo Pharmaceuticals, Inc.
|
|
Portfolio Management a Tool for Our Time
Portfolio Decisions
|
|
Project
Management in Biopharma: A Necessary Evil or a Source of Competitive
Advantage?
Authored by Realization Technologies, Inc.
|
Process
Map Proposal for The Validation of Genomic Biomarkers
Authored by: Federico Goodsaid, US Food and Drug Administration Genomics Group
|
|
Pathway Analysis for Target and Compound
Evaluation
Sudhir Sahasrabudhe, CSO,
Prolexys Pharmaceuticals
|
|
Personalized Healthcare 2010
IBM Business Consulting Services
|
Principled,
Effective Data Mining for Systems Biology
Evan W. Steeg, Ph.D
|
Portfolio Management: a Tool for Our Time
Portfolio Decisions
|
Principled, Effective Data Mining for Systems Biology
Evan W. Steeg, Ph.D., Bridge Technology Consulting
|
Progressive Project Management Focus®:
A Strategy to Accelerate Drug Product Development
By Tim Noffke, Chad Nikel, And Mike Sullivan, Integrated Project
Management Group
|
Protein
Tomography™ Pictures that prove your theory
By Sidec Technologies
|
|
Read more about the Molecular Diagnostics Conference in the February 1, 2007 is of Genetic Engineering News.
|
|
SCREEN
DREAMS: The Promise of Parallel Screening
by Malorye A. Branca
|
Senior Management_Disabler or Enabler of Alliance
Success
by Stuart Kliman &
Christopher Hiserman
|
SNPs as powerful tools for Association
By Applied Biosytems
|
|
Strategic of
Point-of-Care Diagnostics
|
|
Strategic Opportunities In Molecular Diagnostics
Sector Review By TSG Partners
|
|
Strategic Opportunities in Point-of-Care
Diagnostics Sector Review By TSG Partners
|
|
Strategic Opportunities In Genomics Tools
Sector Review By TSG Partners Strategic Advisors
|
Successful Pharmacogenomics Business Models
By Sam Tetlow
|
Template
Synthesized Nanotubes for Biomedical Delivery Applications.
Authored by: Charles Martin et al University of Florida
|
The Consortium for
Metabonomic Toxicology (COMET): Aims, Activities and
Achievements
Authored by: John C Lindon, Imperial College London
|
The Challenge of Improving the Drug Discovery Process - An Early
ADME Perspective
Philip S. Burton, Ph.D., Chief Executive and Scientific Officer,
ADMETRx, Inc.
|
The
Era of ErbB-Receptor-Targeted Therapies: Advances Toward Personalized Medicine
Sarah Bacus et al Targeted Molecular Diagnostics LLC
|
The Future of PCR with the Expiration of PCR Patents
Authored by: Mr. Harry
Glorikian, Partner, TSG-Partners
|
The
Importance of siRNA Delivery in Cancer Target Validation
EiRx
Therapeutics Plc.
|
NEW!
The Impact of Alliances: Perspectives From Endo Pharmaceuticals, Eli Lilly, Pfizer & Biogen Idec
Harry Atkins, Senior Director, Alliance Management, Endo
Pharmaceuticals, Inc.
|
|
The
Importance of Understanding Metabolism in Pharmaceutical Research
Dr. Ala Nassar, Principle
Research Scientist, Drug Metabolism, Vion Pharmaceuticals Inc.
|
|
The Need for a New Molecular Diagnostic Business
Model to Fit the Needs of Personalized Medicine
Peter Keeling, CEO Diaceutics
|
The Next Generation of Immunoassay Technologies
Steven Bodovitzt, Principal, BioPerspectives
|
The
RNAi Patent Steeplechase: Higher Hurdles for Utility and Nonobviousness
in the United States
Foley Hoag LLP
|
|
TaqMan® Gene Expression
Assays for Validating Hits From Fluorescent Microarrays
Applied Biosystems
|
Therapeutic Approaches for Prion Disorders
Article courtesy of: Expert Review of Anti-infective Therapy, Aug. 2007
|
Transcriptional
Profiling of Multiple Sclerosis: Towards Improved Diagnosis and
Treatment
Raija LP Lindberg† and Ludwig Kappos
|
Trends in Library Design and Synthesis
Sukanta Bhattacharyya
|
|
You've
Closed the Deal, Now What? What it Takes to Ensure a Successful
Alliance or Partnership
JMW Consultants Inc.
|
|
